Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

BackgroundNeoadjuvant chemotherapy (nCT) and chemoradiotherapy (nCRT) are the standard treatments in patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC). Adding PD-1 inhibitor to the chemotherapy has shown significant clinical benefits in first-line treatment of advan...

Full description

Bibliographic Details
Main Authors: Huilai Lv, Yang Tian, Jiachen Li, Chao Huang, Bokang Sun, Chunyue Gai, Zhenhua Li, Ziqiang Tian
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Oncology
Subjects:
esophageal squamous cell carcinoma
pathologic complete response
combination therapy
immune checkpoint inhibitors
sintilimab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.864533/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.864533/full

Similar Items